Previous 10 | Next 10 |
ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral and poster present...
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolu...
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its third quarter 2023 financial...
2023-10-26 00:24:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For the extreme gambler who has done homework regarding risk and rewards, few thrills excite as much as cheap stocks to buy under $1. By logical deduction, of course, we’re talking about...
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc...
2023-10-08 09:40:00 ET Summary Jiangsu QYuns Therapeutics has filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Taiwan’s PharmaEssentia has acquired a myeloid immune checkpoin...
- Continued Progress in the Global Development and Commercialization of XIPERE ® (known as ARCATUS ® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of t...
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Charles A. Deignan, Chief Financ...
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D....
2023-08-14 16:20:28 ET Clearside Biomedical press release ( NASDAQ: CLSD ): Q2 GAAP EPS of -$0.15 misses by $0.01 . Revenue of $1.02M (+168.4% Y/Y) beats by $0.95M . As of June 30, 2023, Clearside’s cash and cash equivalents totaled $35.0 million. The Co...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Curren...
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therap...
The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concer...